Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SLX4IP CRISPR Activation Plasmid (h): sc-407109-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SLX4IP CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- SLX4IP CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by SLX4IP CRISPR Activation Plasmid (h) and SLX4IP CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the SLX4IP transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SLX4IP Antibody (G-4): sc-377066
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SLX4IP CRISPR Activation Plasmid (h) | sc-407109-ACT | 20 µg | $397.00 |
Human SLX4IP (SLX4 interacting protein) is a nuclear factor implicated in the maintenance of genome integrity through interactions with structure-specific endonuclease networks and DNA repair scaffolds. It has been linked to pathways governing replication-associated DNA damage responses, telomere homeostasis, and resolution of complex DNA structures that can arise during replication stress. Altered SLX4IP expression has been associated with telomere length regulation mechanisms that influence cellular proliferative capacity and genome stability phenotypes. These functions make SLX4IP a useful target for investigating DNA repair pathway wiring, chromosomal stability, and stress-adaptive programs relevant to cancer and other genome-instability–associated conditions.
SLX4IP CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SLX4IP expression without altering the underlying DNA sequence.
SLX4IP CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SLX4IP locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SLX4IP transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous SLX4IP expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SLX4IP locus and enabling the study of SLX4IP-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of SLX4IP pathway restoration in tumor cells with silenced or reduced SLX4IP expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.